Engineering Superior Treatments for Patients with Life-Threatening and Function-Threatening Diseases

 

About Valitor

Valitor’s technology enables us to engineer BioBetter products with previously unattainable pharmacological properties to maximize clinical impact 

Our technology

Our core technology platform originated at UC Berkeley and enables us to generate multivalent protein (MVP) conjugates by tethering multiple copies of bioactive molecules (e.g., camelid antibodies, cytokines, etc.) to single-chain, soluble biopolymers. Using Valitor’s propriety compositions and chemistry methods, our MVPs exhibit the following advantages over other therapeutic products that are either on the market or in development:

Extended Target Tissue Retention

Superior Pharmacokinetics

Protection from Deactivation

Engineered for

High Potency

Designed from Endogenous Materials

Superior Pharmaco-stability

Superior Pharmacodynamics

Superior Safety Profile

 
Awards
1200px-US-NIH-NCI-Logo.svg.png
bplan_logo_new_v2-262_edited.png

Semi finalist 2011

NEI.png
pharmadirections.png

California JumpStart Award 2016

NIGMS.png
QB3_logo_Navy_2.png
NIAMS.png
FAST_New-Logo_102018-1024x280.png
Investors
 
 
Contact Us

Valitor, Inc.
East Bay Innovation Center
820 Heinz Avenue
Berkeley, CA 94710

Phone: (510) 545-6062
Fax: (510) 647-8429
Email: info@valitorbio.com

Please download our preview slide deck

for additional information about Valitor